Outbreaks of bird flu in mammals more than doubled across the world last year, raising the risk that the virus could ...

Moderna isn’t giving up on the combo shot entirely—it plans to resubmit later this year after it collects more data from its ...

Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...

Moderna voluntarily pressed pause on its request to license its vaccine candidate, mRNA-1083 — which combines vaccines for seasonal influenza and covid and is intended for people over 50 — until it ...

As bird flu sweeps across US poultry and cattle farms, researchers are racing to find ways to contain the outbreaks before ...

The first major global review of bird flu in cats reveals an emerging threat of a potential human pandemic. Spring is here, ...

An experimental evaluation of the risk of influenza transmission from contaminated objects finds that viable virus was rarely ...

Today vaccine maker Moderna announced it voluntarily pulled its licensing submission for the combination seasonal ...

This week, mRNA vaccines are set to face intense scrutiny from critics in Congress. Here's an explainer of how we know they ...

Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination Covid and flu ...

During a call with U.S. doctors this month, one CDC official noted that there is a seasonality to bird flu: Cases peak in the ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. | San Diego ...